Chrysalis Technologies

Chrysalis Technologies is a medical technology company specializing in the development of advanced aerosol delivery systems. Originally a division of Altria (Philip Morris USA), the company developed the proprietary Capillary Aerosol Technology (CAT), which enables the delivery of high-purity, thermally stable aerosols for inhalation. The technology is designed to provide rapid systemic delivery of drugs, comparable to intravenous administration, without the need for needles. In 2013, Philip Morris International acquired the company's intellectual property and assets for $110 million to bolster its "Beyond Nicotine" and life sciences strategy. Today, the platform is utilized to develop respiratory drug delivery solutions and wellness products under the Philip Morris International umbrella. The company's innovations focus on achieving precise dosing and rapid onset of action for a variety of therapeutic compounds.